ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

KRYS Krystal Biotech Inc

177.78
-4.94 (-2.70%)
15 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Krystal Biotech Inc NASDAQ:KRYS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -4.94 -2.70% 177.78 140.00 184.64 181.25 174.29 180.21 492,509 01:00:00

Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

20/02/2024 12:00pm

GlobeNewswire Inc.


Krystal Biotech (NASDAQ:KRYS)
Historical Stock Chart


From Dec 2023 to Jun 2024

Click Here for more Krystal Biotech Charts.

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, will report its fourth quarter and full year 2023 financial results on Monday, February 26, 2024, prior to the open of U.S. markets. Subsequently, at 8:30 am ET, the Company will host a webcast to discuss the financial results and provide a business update.

Investor Conference Call

The Company will host an investor webcast on Monday, February 26, 2024 at 8:30 am ET.

Investors and the general public can access the live webcast at https://www.webcaster4.com/Webcast/Page/3018/49928.

For those unable to listen to the live webcast, a replay will be available for 30-days on the Investors section of the Company’s website at www.krystalbio.com.

About Krystal Biotech, Inc.Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).

CONTACTInvestors and Media:                                                              Meg Dodge                                                       Krystal Biotech                                                     mdodge@krystalbio.com                                  

1 Year Krystal Biotech Chart

1 Year Krystal Biotech Chart

1 Month Krystal Biotech Chart

1 Month Krystal Biotech Chart

Your Recent History

Delayed Upgrade Clock